Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia

A benign prostatic hyperplasia technology, applied in the direction of drug combination, biological material analysis, DNA/RNA fragment, etc., to achieve the effect of preventing and treating benign prostatic hyperplasia

Active Publication Date: 2022-06-28
THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Whether MAT2A and MAT2B play a role in the occurrence and development of benign prostatic hyperplasia has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia
  • Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia
  • Application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1. mRNA expression levels of MAT2A and MAT2B in benign prostatic hyperplasia tissue.

[0030] The invention provides the application of MAT2A and MAT2B as molecular targets in early screening of patients and early diagnosis of benign prostatic hyperplasia. The mRNA expression levels of MAT2A and MAT2B in benign prostatic hyperplasia tissues were detected by PCR method, which were higher than those in normal prostate tissues.

[0031] From January 2021 to December 2021, the First Affiliated Hospital of China Medical University admitted 50 inpatients with benign prostatic hyperplasia (BPH group), aged (66.15±7.33) years old; all patients underwent transurethral resection of the prostate, and the postoperative pathological diagnosis was confirmed For benign prostatic hyperplasia tissue. Another 50 patients (Normal group) who underwent radical bladder cancer surgery during the same period were selected, aged (63.62±5.28) years old. Tissue specimens of benign prost...

Embodiment 2

[0035] Example 2. Protein expression levels of MAT2A and MAT2B in benign prostatic hyperplasia tissue.

[0036] The invention provides the application of MAT2A and MAT2B as molecular targets in early screening of patients and early diagnosis of benign prostatic hyperplasia. Western blotting experiments showed that the protein expression levels of MAT2A and MAT2B in benign prostatic hyperplasia tissues were higher than those in normal prostate tissues.

[0037] From January 2021 to December 2021, the First Affiliated Hospital of China Medical University admitted 50 inpatients with benign prostatic hyperplasia (BPH group), aged (66.15±7.33) years old; all patients underwent transurethral resection of the prostate, and the postoperative pathological diagnosis was confirmed For benign prostatic hyperplasia tissue. Another 50 patients (Normal group) who underwent radical bladder cancer surgery during the same period were selected, aged (63.62±5.28) years old. Tissue specimens of ...

Embodiment 3

[0041] Example 3. The protein expression of MAT2A and MAT2B in WPMY-1 cells can be down-regulated using the specific inhibitor PF-9366.

[0042] The present invention provides the application of MAT2A and MAT2B as molecular targets in screening or preparing drugs for preventing and / or treating benign prostatic hyperplasia. The use of MAT2A and MAT2B specific inhibitor PF-9366 can reduce the proliferation ability of WPMY-1 cells; the use of specific inhibitor PF-9366 can also reduce the down-regulation of MAT2A and MAT2B expression in WPMY-1 cells.

[0043] Human normal prostate stromal immortalized cells WPMY-1 were cultured in DMEM (10% FBS, 1% penicillin-streptomycin) at 37 °C, 5% CO2, and 0.25% when the cell density was 80%. Trypsinization was used for subsequent experiments.

[0044] WPMY-1 cells were treated with PF-9366 at 500 nmol / L for 24 h, 48 h and 72 h before subsequent experiments.

[0045] Western blotting was used to detect the protein expression levels of MAT2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biotechnology and benign prostatic hyperplasia, and particularly relates to application of MAT2A and MAT2B as drug targets for detecting or treating benign prostatic hyperplasia. The invention discloses biomarkers MAT2A and MAT2B related to benign prostatic hyperplasia, and also discloses application of the MAT2A and MAT2B as markers in preparation of a product for diagnosing benign prostatic hyperplasia. According to the present invention, the expression of MAT2A and MAT2B is down-regulated by using the specific inhibitor PF-9366 and siRNA, and the proliferation ability of the human prostate epithelial cell line WPMY-1 cell is inhibited so as to achieve the effect of preventing and treating benign prostatic hyperplasia, such that the application in the preparation of the benign prostatic hyperplasia treatment drug can be provided. The invention finds that MAT2A and MAT2B from human can be used as new molecular drug targets for detecting or treating benign prostatic hyperplasia for the first time, and the target can be utilized to achieve the purpose of benign prostatic hyperplasia detection or drug screening, so that a new thought and gene resources are provided for prevention and treatment of benign prostatic hyperplasia.

Description

technical field [0001] The invention belongs to the technical field of biotechnology and benign prostatic hyperplasia, in particular to MAT2A (methionine adenosyl transferase 2A) and MAT2B (methionine adenosyl transferase 2B) as drug targets for detecting or treating benign prostatic hyperplasia Applications. Background technique [0002] Benign prostatic hyperplasia (BPH) is an age-related disease and a common urological disease with chronic progressive development in middle-aged and elderly men. Quality of Life. The incidence is >60% in men over the age of 60, reaching more than 69% at the age of 70. The incidence of BPH often increases with age, and drug treatment is mostly 5α-reductase inhibitors, α-blockers, hormones, etc., but the application of adverse drug reactions and drug tolerance is limited. Surgical treatment is generally considered to be the first choice for the radical cure of BPH, but the patient's advanced age often makes surgical treatment limited. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883C12N15/11G01N33/573G01N33/68C12N15/113A61K31/437A61K31/7105A61P13/08
CPCC12Q1/6883G01N33/6893G01N33/573C12N15/1137C12Y205/01006A61K31/437A61K31/7105A61P13/08C12Q2600/158G01N2333/91171G01N2800/342C12N2310/141A61K2300/00
Inventor 张哲张国君
Owner THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com